No Detail Found!

Exploring Oral Immunotherapeutics in Oncology: Uses, Side Effects Novel Approaches, Challenges, and Future Prospects

Author(s)
Kalya Ahmad Sandhu Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Asawar Yameen Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Naima Zafar Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Hira Ali Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Usama Abid Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Mishkaat Raza Saulat Institute of Pharmaceutical Sciences & Drug Research, Quaid-I-Azam University, Islamabad, Pakistan.
Abstract
Immunotherapy is a medical intervention in which certain immune system components are used to combat disease. Usually, immunotherapy works by helping the body fight off the offending substance by modifying it as well as boosting the immune system. Biologic therapy or biotherapy are additional terms for certain forms of immunotherapy. Different advances and novel approaches have been studied such as cancer vaccines, immune checkpoint inhibitors, monoclonal antibodies, etc. Oral immunotherapeutics are used in a variety of solid tumors and hematological malignancies but still, these immunotherapeutics have their own limitations and adverse effects. Management of these side effects and optimization of therapeutic benefits remains a challenge. Moreover, challenges such as patient selection, dose optimization, and medication resistance are major issues that hinder the widespread use of oral immunotherapeutics. However, the future of oral immunotherapy in oncology seems to be promising due to the new advancements and research done.
Publication Details
Page(s) 9-17
Published Journal: Global Pharmaceutical Sciences Review, Volume: 9, Issue: 2, Year: 2024

Request the full text from PASTIC

Keywords
Challenges, adverse effects, Cancer, Combination Therapies, Advancement in Immunotherapy, Oral Immunotherapeutic, ADCs, Immunotherapeutic, Targeted Therapies
References
Bai R.,Chen N.,Li L.,Cui J. .2021 .A brand new era of cancer immunotherapy: breakthroughs and challenges. Chinese Medical Journal, 134(11) : 1267-1275.
Baker D.,Herrod S. S.,Alvarez-Gonzalez C.,Giovannoni G.,Schmierer K. .2017 .Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurology, 74(8) : .
Cohen R. B. .2003 .Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clinical Colorectal Cancer, 2(4) : 246-251.
Coop C. A.,Tankersley M. S. .2008 .Patient perceptions regarding local reactions from allergen immunotherapy injections. Annals of Allergy Asthma & Immunology, 1206(10) : 60841-1.
Disis M. L. .2014 .Mechanism of action of immunotherapy. , 09 : S3-S13.
Dobosz P.,Dziecitkowski T. .2019 .The intriguing history of cancer immunotherapy. Frontiers in Immunology, 10 : .
Hu Y.,Turner M. J.,Shields J.,Gale M. S.,Hutto E.,Roberts B. L.,Siders W. M.,Kaplan J. M. .2009 .Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology, 03115(2) : 2567-270.
Karmakar S.,Dhar R.,Seethy A.,Singh S.,Pethusamy K.,Srivastava T.,Talukdar J.,Rath G. .2021 .Cancer immunotherapy: Recent advances and challenges. Journal of Cancer Research and Therapeutics, 1241(4) : .
Klotz L.,Meuth S. G.,Wiendl H. .2011 .Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clinical Immunology, 04(1) : 25-30.
National Cancer Institute. .2019 .Monoclonal antibodies. , : .
Peterson C.,Denlinger N.,Yang Y. .2022 .Recent advances and challenges in cancer immunotherapy. Cancers, 3972(16) : .
Thorpe P. E.,Ross W. C. J.,Cumber A. J.,Hinson C. A.,Edwards D. C.,Davies A. J. S. .1978 .Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin. Nature, 271(5647) : 752-755.
Turner M. J.,Chretien N.,Havari E.,Roberts B. L.,Kaplan J. M.,Siders W. M. .2013 .Immune status following alemtuzumab treatment in human CD52 transgenic mice. Journal of Neuroimmunology, 04(1-2) : 29-36.
Umapathy V. R.,Natarajan P. M.,Swamikannu B. .2023 .Review of the role of nanotechnology in overcoming the challenges faced in oral cancer diagnosis and treatment. Molecules, 5395(14) : .
Vasileiou M.,Papageorgiou S.,Nguyen N. P. .2023 .Current advancements and future perspectives of immunotherapy in breast cancer treatment. Immuno, 3(2) : 195-216.
Waldman A. D.,Fritz J. M.,Lenardo M. J. .2020 .A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews. Immunology, 20(11) : 651-668.
Weth F. R.,Hoggarth G. B.,Weth A. F.,Paterson E.,White M. P. J.,Tan S. T.,Peng L.,Gray C. .2023 .Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer, 130(5) : 703-715.
0

Citations

0

Downloads

56

Views